Advanced AKI Nursing Guide

AKI Definition & KDIGO Staging

KDIGO 2012 Definition: AKI is present when ANY ONE of the following criteria is met: Serum creatinine rise ≥26.5 μmol/L within 48 hours, OR creatinine rise to ≥1.5× baseline within 7 days, OR urine output <0.5 mL/kg/hr for ≥6 hours.

📊KDIGO AKI Staging Criteria

Stage	Serum Creatinine Criterion	Urine Output Criterion	Severity
Stage 1	1.5–1.9× baseline or rise ≥26.5 μmol/L	<0.5 mL/kg/hr for 6–12 hours	Mild
Stage 2	2.0–2.9× baseline	<0.5 mL/kg/hr for ≥12 hours	Moderate
Stage 3	≥3× baseline, OR absolute ≥353.6 μmol/L, OR initiation of RRT, OR eGFR <35 mL/min (<18 yr)	<0.3 mL/kg/hr for ≥24h, OR anuria ≥12 hours	Severe

Use the higher of creatinine vs urine output staging when both criteria are met. Stage using all available data.

⚡Urine Output Definitions

Normal: ≥0.5 mL/kg/hr (adult ICU target ≥0.5–1 mL/kg/hr)
Oliguria: <0.5 mL/kg/hr (or <400 mL/24h in adults)
Severe oliguria: <0.3 mL/kg/hr for ≥24h
Anuria: <100 mL/24h (or <50 mL/12h)

Note: Catheterise all patients with AKI for accurate hourly urine output monitoring.

📋Baseline Creatinine

Use most recent stable creatinine within 3–12 months
If unknown: assume creatinine consistent with eGFR 75 mL/min/1.73m² (MDRD back-calculation)
In GCC: consider lower muscle mass in elderly/malnourished patients — creatinine may underestimate AKI severity
Rising creatinine trend is as important as absolute value

🔬Pre-Renal vs Intrinsic vs Post-Renal Distinction

Pre-Renal AKI

FENa <1% (tubules intact, avid Na reabsorption)
FeUrea <35%
Urine Na <20 mmol/L
Urine osmolality >500 mOsm/kg
Urine:plasma creatinine ratio >40
Responds to fluid challenge

Intrinsic Renal AKI

FENa >2% (tubular dysfunction)
FeUrea >50%
Urine Na >40 mmol/L
Urine osmolality <350 mOsm/kg
Urinary sediment: casts (granular/RBC/WBC)
Haematuria/proteinuria on dipstick

Post-Renal AKI

Variable FENa (early = low, late = high)
Hydronephrosis on ultrasound
Bilateral obstruction needed for AKI (or single functioning kidney)
Bladder scan: retention >300 mL
Urgent catheterisation if retention
Urology/nephrology referral

FENa (%) = [ (Urine Na × Plasma Cr) / (Plasma Na × Urine Cr) ] × 100
FeUrea (%) = [ (Urine Urea × Plasma Cr) / (Plasma Urea × Urine Cr) ] × 100

FENa caveat: FENa unreliable if patient on diuretics (falsely elevated). Use FeUrea instead (<35% = pre-renal). Also unreliable in contrast nephropathy, myoglobinuria, and early obstruction.

Causes & Clinical Assessment

💧Pre-Renal Causes (Most Common)

Hypovolaemia: haemorrhage, GI losses (vomiting/diarrhoea), burns, diuretic excess, poor oral intake
Sepsis: vasodilation → renal hypoperfusion (most common ICU cause)
Cardiac failure: low output → reduced renal perfusion (cardiorenal syndrome)
Hepatorenal syndrome: cirrhosis → splanchnic vasodilation → severe renal vasoconstriction
Abdominal compartment syndrome: raised intra-abdominal pressure >20 mmHg
NSAIDs: block prostaglandin-mediated afferent arteriole dilation → pre-renal in at-risk patients

🔬Intrinsic Renal Causes

Acute Tubular Necrosis (ATN) — Commonest Intrinsic

Ischaemic ATN: prolonged pre-renal ischaemia → tubular cell death
Nephrotoxic ATN: aminoglycosides, contrast, myoglobin, haemoglobin, cisplatin

Glomerulonephritis (GN)

Rapidly progressive GN (anti-GBM, ANCA-vasculitis, immune complex)
Nephrotic syndrome with AKI

Tubulointerstitial Nephritis (TIN)

Drug-induced: NSAIDs, PPIs (omeprazole), penicillins, cephalosporins, rifampicin
Infection-associated: pyelonephritis

Thrombotic Microangiopathy (TMA)

HUS (haemolytic uraemic syndrome) — especially STEC O157
TTP (thrombotic thrombocytopenic purpura) — ADAMTS13 deficiency

🔴Post-Renal Causes

Intraluminal

Renal stones (bilateral or single kidney)
Papillary necrosis fragments
Blood clots
Ureteral strictures

Extrinsic Compression

Pelvic/retroperitoneal malignancy
Lymphadenopathy
Retroperitoneal fibrosis
Pregnancy complications

Bladder/Urethral

BPH (very common in GCC — older men)
Bladder cancer
Neurogenic bladder
Urethral stricture

Bladder Scan First: In all male patients with AKI and oliguria, perform bladder scan immediately. Urinary retention >300 mL — insert catheter urgently. This is a rapidly reversible cause of AKI.

Clinical Assessment Framework

🩺Fluid Status Examination

Signs of Hypovolaemia (pre-renal)

JVP not visible / flat (head 45°)
Dry mucous membranes, sunken eyes
Reduced skin turgor (less reliable in elderly)
Postural hypotension (drop >20 mmHg systolic)
Tachycardia, cool peripheries
Weight loss >baseline

Signs of Fluid Overload

JVP elevated (>4 cm above sternal angle)
Peripheral oedema (graded 1+–4+)
Pulmonary oedema / bibasal crackles
Third heart sound (S3 gallop)
Ascites (hepatomegaly in cardiac failure)
Weight gain >baseline

🧪Investigations Priority

Urine Dipstick: Blood + Protein = glomerular cause (GN). Blood alone = ATN, papillary necrosis. Nitrite/leucocytes = UTI/pyelonephritis

Urine Microscopy: RBC casts = GN; granular/muddy brown casts = ATN; WBC casts = interstitial nephritis/pyelonephritis; waxy casts = advanced CKD/severe AKI

Renal Ultrasound: Bilat hydronephrosis = obstruction; small kidneys = CKD; normal = ATN/GN likely; bladder for post-void residual

Bloods: U&E, creatinine trend, FBC (microangiopathic anaemia = HUS/TTP), LFT, CRP/procalcitonin, ANCA/anti-GBM if GN suspected, CK (rhabdomyolysis), lactate (sepsis)

Urine biochemistry: FENa, FeUrea, Na, creatinine, osmolality, protein:creatinine ratio (PCR) or albumin:creatinine ratio (ACR)

🏥Nephrology Referral Criteria

Urgent Referral (Same Day)

AKI Stage 3
Suspected rapidly progressive GN (blood + protein on dipstick, no obvious cause)
AKI + suspected TTP/HUS (thrombocytopenia + microangiopathic haemolytic anaemia)
AKI + systemic vasculitis features
RRT consideration needed
AKI in renal transplant

Early Referral (48–72h)

AKI Stage 2 not responding to treatment
AKI + proteinuria >1g/day or haematuria (GN workup needed)
Unknown cause of AKI
AKI in CKD patients (CKD stage 3b+)
Recurrent AKI
AKI in myeloma/paraproteinaemia

Nephrotoxin Identification & Management

PRIORITY ACTION: On diagnosis of AKI, immediately review ALL medications and STOP nephrotoxins unless absolutely essential. This is the single most impactful reversible intervention.

✕STOP Immediately — High Priority

NSAIDs (ibuprofen, diclofenac, naproxen, ketorolac) — afferent arteriole constriction
ACE Inhibitors (ramipril, enalapril, lisinopril) — hold until AKI resolved and volume status optimised
ARBs (losartan, valsartan, irbesartan) — same mechanism as ACEi
Diuretics (unless managing fluid overload) — worsens pre-renal AKI
Metformin — lactic acidosis risk in AKI (hold when creatinine rising)
SGLT2 inhibitors (empagliflozin, dapagliflozin) — volume depletion risk
Combined renin-angiotensin blockade — ACEi + ARB or + aliskiren

!Use with Extreme Caution / Monitor Levels

Aminoglycosides (gentamicin, amikacin) — only if no alternative; single daily dosing preferred; trough levels essential; avoid >5 days
Vancomycin — AUC-guided dosing (AUC/MIC 400–600); avoid trough-only monitoring; nephrotoxicity risk especially with piperacillin-tazobactam combination
Amphotericin B — liposomal formulation preferred; monitor creatinine/K+/Mg²+ daily
Ciclosporin / Tacrolimus — trough levels; dose reduction needed in AKI
Cisplatin — pre-hydration mandatory; monitor Mg²+
IV Contrast agents — see contrast section below
Tenofovir (HIV treatment) — renal tubular toxicity; monitor urine protein/phosphate

💉Contrast-Induced AKI (CI-AKI) Prevention Protocol

CI-AKI Risk Factors: eGFR <60, diabetes, heart failure, volume depletion, multiple myeloma, concurrent nephrotoxins, large contrast volume, intra-arterial > IV route. High risk in GCC due to high cardiovascular disease burden and frequent angiography.

Pre-Hydration Protocol (Standard)

0.9% NaCl 1 mL/kg/hr for 12 hours before AND 12 hours after contrast
Alternatively (if time limited): 3 mL/kg/hr for 1 hour before, then 1 mL/kg/hr for 6 hours after
Sodium bicarbonate 1.26% (150 mEq/L): 3 mL/kg/hr for 1h pre + 1 mL/kg/hr for 6h post — alternative, no clear superiority over NaCl
Oral hydration only if mild risk and eGFR >45

Additional Measures

Use iso-osmolar or low-osmolar non-ionic contrast (iodixanol, iohexol)
Use minimum contrast volume possible
Avoid repeat contrast within 48–72h
NAC (N-acetylcysteine): 1200 mg PO BD pre/post — controversial; PRESERVE trial showed no benefit, but low risk so some centres continue
Hold metformin 48h before and restart when creatinine stable
Check creatinine 48h post-contrast

💪Rhabdomyolysis-Induced AKI

Myoglobin nephrotoxicity: CK >5000 U/L significantly increases AKI risk. CK >15,000 U/L = high risk. Target aggressive urine alkalinisation and high-volume hydration.

Causes in GCC Context

Heat stroke — construction workers, outdoor workers in summer (very common in GCC)
Trauma/crush injury
Prolonged immobility (seizures, coma)
Extreme exertion (military/sport)
Statins (especially with P450 interactions)
Alcohol/drug toxicity
Inflammatory myopathies

Management Protocol

Aggressive IV fluid resuscitation: 0.9% NaCl or Hartmann's 200–300 mL/hr initially
Target urine output >200–300 mL/hr (3 mL/kg/hr) until myoglobinuria clears
Urine alkalinisation: sodium bicarbonate (controversial — target urine pH >6.5)
Monitor: CK every 6–12h until trend down, U&E, Ca²+/PO₄ (hypocalcaemia early, hypercalcaemia in recovery)
Avoid calcium supplementation unless symptomatic hypocalcaemia (Ca²+ can deposit in muscle)
Watch for hyperkalaemia — most urgent electrolyte emergency

🌿Herbal Nephrotoxins — GCC Relevance

Aristolochic Acid Nephropathy

Found in some traditional Chinese herbal preparations and some traditional Middle Eastern/Asian remedies
Causes rapidly progressive tubulointerstitial nephritis → irreversible renal failure
High prevalence in patients using traditional medicines without disclosure to doctors
Ask specifically: "Do you take any herbal or traditional medicines?"
No specific treatment — stop exposure, supportive care, nephrology referral

Other Herbal Nephrotoxins

Chromium picolinate — interstitial nephritis
Cape aloe — ATN
Licorice root (excessive) — hypertension/hypokalaemia
Thunder God Vine — ATN
Always document all supplements, vitamins, traditional medicines on medication review
Non-judgmental questioning — patients may not volunteer this information

Fluid Management in AKI

💧Fluid Resuscitation for Pre-Renal AKI

Key Principle: Treat fluid-responsive pre-renal AKI promptly with crystalloid boluses. However, avoid indiscriminate fluid loading — over-resuscitation causes harm (pulmonary oedema, abdominal compartment syndrome, worsened AKI).

Fluid Challenge Protocol

Give 250–500 mL crystalloid bolus over 15–30 minutes. Balanced crystalloids (Hartmann's / Plasmalyte) preferred over 0.9% NaCl for large volumes (reduces hyperchloraemic acidosis)

Reassess after each bolus: HR, BP, JVP, skin perfusion, urine output. If improving → may repeat bolus. If no response after 1–2L → stop and reassess cause

Fluid responsiveness assessment: Passive leg raise (PLR) — raise legs 45°, measure CO/BP change over 1 min. Rise >10% = fluid responsive. More reliable than static measures.

Sepsis/haemodynamic compromise: Target MAP ≥65 mmHg; if vasopressors needed → norepinephrine first choice; avoid aggressive fluid beyond initial resuscitation (SMART trial data)

Fluid Choice

PREFERRED

Balanced crystalloids: Hartmann's (Lactated Ringer's), Plasmalyte
Lower risk of hyperchloraemic acidosis vs 0.9% NaCl
SMART & SALT-ED trials: lower major adverse kidney events

ACCEPTABLE

0.9% NaCl: appropriate for volume resuscitation, hypochloraemic alkalosis, contrast pre-hydration, hyponatraemia
Human albumin solution (HAS 4–5%): consider in cirrhosis/hepatorenal syndrome, sepsis (SAFE trial)

AVOID

Gelatin colloids (gelofusin) — increased AKI risk
Hetastarch (HES) — increased AKI/RRT in sepsis (6S/CHEST trials)
Dextrose solutions for resuscitation — no oncotic benefit

📊Urine Output Monitoring

Catheter & Monitoring

Insert urinary catheter in all oliguric/AKI patients for hourly monitoring
Record urine output EVERY HOUR in ICU/HDU patients
Record every 4–6 hours in ward patients (minimum)
Daily weight (most reliable fluid balance measure — 1 kg ≈ 1L fluid)
Strict fluid balance: all inputs AND outputs (including insensible losses ~500–800 mL/day)

Diuretic Use in AKI

Furosemide role: to MANAGE fluid overload in oliguric AKI — NOT to convert oliguria to non-oliguria
High doses often needed: 80–250 mg IV (tubular secretion impaired)
Furosemide infusion: 10–20 mg/hr after loading dose
Furosemide stress test: 1 mg/kg IV (furosemide-naive) — UO <200 mL/2h predicts AKI progression to Stage 3
Do not use diuretics to avoid dialysis — FACTT trial: no benefit in outcome
Ensure adequate volume status before furosemide — never give in hypovolaemia

⚡Hyperkalaemia Management in AKI

EMERGENCY: Hyperkalaemia ≥6.0 mmol/L with ECG changes = immediate life-threatening emergency. Check ECG: peaked T waves → wide QRS → sine wave → VF/asystole progression.

K+ 5.0–5.5

Dietary restriction (low-K+ diet). Stop K+-sparing diuretics, ACEi/ARB. Monitor every 4–6h. Recheck potassium. Mild measures only.

K+ 5.5–6.0

Calcium resonium (sodium polystyrene sulfonate) 15–30g PO/PR; dietary restriction. Loop diuretic if volume replete. Close monitoring q2–4h.

K+ 6.0–6.5

Start treatment protocol. If ECG changes → treat as emergency. Insulin-dextrose: Actrapid 10 units IV + 50 mL 50% dextrose (or 125 mL 20% dextrose). Monitor BG q30min × 4h. Onset 15–30 min. Duration 2–4h. May repeat.

K+ >6.5 or ECG changes

EMERGENCY — do all simultaneously:
1. IV Calcium gluconate 10% 10–20 mL over 5–10 min (MEMBRANE STABILISER — onset 1–3 min, duration 30–60 min; does NOT lower K+). Repeat if ECG not improved. CAN give 2nd dose after 5 min if no response.
2. Insulin-dextrose as above (redistribute K+ into cells)
3. Salbutamol 10–20 mg via nebuliser (redistributes K+ — additive effect with insulin; onset 15–30 min)
4. IV Sodium bicarbonate 8.4% 50 mmol if acidosis present (pH <7.2) — redistributes K+ by correcting acidosis
5. Calcium resonium 30g for elimination (onset hours)
6. Consider RRT urgently if refractory or rising despite treatment

Calcium gluconate is cardioprotective only — it does not lower serum K+. Always follow with redistributive therapy. Continuous cardiac monitoring mandatory.

🧪Other Electrolyte Management

Phosphate

Hyperphosphataemia common in AKI (reduced excretion)
Dietary phosphate restriction: avoid high-phosphate foods (dairy, nuts, processed meats, cola drinks)
Phosphate binders with meals: calcium carbonate/acetate or sevelamer (if severe)
Target PO₄ <1.6 mmol/L

Sodium

Hyponatraemia in AKI: often dilutional (fluid overload) or from hypotonic fluid replacement
Correct slowly if severe: max 8–10 mmol/L/day (risk of osmotic demyelination if corrected too fast)
Hypernatraemia: free water deficit — correct with 5% dextrose, monitor Na q4–6h

Metabolic Acidosis

Common in AKI — reduced H+ excretion and bicarbonate loss
Sodium bicarbonate: consider if pH <7.15 or bicarbonate <10 mmol/L (worsens hypocalcaemia)
RRT if severe refractory acidosis is an AEIOU indication
Monitor ABG/VBG in sick patients

Renal Replacement Therapy (RRT)

🚨RRT Indications — AEIOU Mnemonic

Acidosis

Metabolic acidosis pH <7.15 refractory to medical management

Electrolytes

Hyperkalaemia K+ >6.5 mmol/L refractory to medical treatment, or life-threatening hyperkalaemia

Intoxication

Dialysable toxins: methanol, ethylene glycol, lithium, salicylates, metformin (severe lactic acidosis)

Overload

Fluid overload refractory to diuretics: pulmonary oedema, inability to provide nutrition

Uraemia

Uraemic symptoms: encephalopathy, pericarditis, coagulopathy, bleeding. Urea typically >30–35 mmol/L symptomatic

Timing Controversy: STARRT-AKI trial (NEJM 2020): no benefit to early RRT initiation vs standard (delayed) strategy in critically ill AKI. Wait for definitive AEIOU indication unless clinical urgency demands earlier start.

🔄RRT Modality Choice

Modality	Indication	Advantage	Disadvantage
CRRT Continuous RRT	Haemodynamically unstable, ICU patients, cerebral oedema, fluid overload requiring slow removal	Slow gentle fluid/solute removal; maintains haemodynamic stability; allows continuous anticoagulation	Requires ICU; continuous anticoagulation; circuit clotting; immobility; higher cost
IHD Intermittent HD	Haemodynamically stable; urgent electrolyte/uraemia correction; toxin removal	Rapid solute clearance; mobility between sessions; lower cost; established technique	Haemodynamic instability risk; rapid fluid/osmolality shifts; not suitable for unstable patients
SLED / PIRRT Sustained low-efficiency dialysis	Haemodynamically intermediate; HDU/step-down patients; when CRRT unavailable	Slower than IHD; less anticoagulation than CRRT; uses IHD machine; better haemodynamic tolerance than IHD	Prolonged staff time; intermediate complexity; not all centres have protocol
PD Peritoneal Dialysis	Resource-limited settings; paediatrics; anticoagulation contraindicated; no vascular access	No vascular access; no anticoagulation; gentle fluid removal	Slower clearance; peritonitis risk; not suitable with abdominal pathology; suboptimal in hypercatabolic states

🔐Anticoagulation in CRRT

Citrate Regional Anticoagulation (Preferred)

Citrate chelates ionised calcium in circuit → prevents clotting
Calcium infused back systemically to replace chelated Ca²+
Advantage: regional anticoagulation (no systemic effect) — safe in high bleeding risk
Monitor: ionised Ca²+ in circuit (target 0.25–0.35 mmol/L) and systemic (target 1.0–1.2 mmol/L)
Risk: citrate accumulation in liver failure (total:ionised Ca²+ ratio >2.5 = accumulation)

Heparin Anticoagulation

Standard unfractionated heparin: 500–2000 units/hr; target aPTT 45–65 sec (circuit) or systemic 40–60 sec
Higher circuit clotting rates vs citrate
Contraindicated in HIT (use argatroban or citrate)
No anticoagulation: short filter survival (3–6h); use if very high bleeding risk

📈AKI Recovery & RRT Weaning

Recovery Definition: Sustained reduction in creatinine toward baseline, increasing urine output without diuretics, absence of further AEIOU criteria.

Signs of Renal Recovery

Urine output increasing despite no/reduced diuretics
Creatinine trending downward on serial measurements
UO >400 mL/day (without diuretics) = sufficient to stop RRT
Electrolytes and acid-base manageable without RRT

RRT Weaning Steps

Trial off CRRT (4–6h interruption) — assess UO and creatinine trend
If UO maintained >30 mL/hr consistently → trial of RRT cessation
Furosemide stress test to assess tubular function recovery
Not all AKI recovers — AKI → CKD transition: follow-up nephrology essential at 3 months post-AKI

30–40% of AKI Stage 3 patients have incomplete recovery → CKD. AKI is a major modifiable risk factor for CKD development.

🩺Vascular Access for RRT

Preferred Sites

Right internal jugular vein — first choice (straight path to RA, lower infection risk vs femoral)
Femoral vein — quick access, if IJV unavailable; higher infection risk; limit mobility
Left IJV — second choice (less preferred — tortuous path)
Subclavian — avoid (risk of subclavian stenosis → affects future AV fistula)

Catheter Care

Strict aseptic technique for all line accesses
Daily inspection of insertion site
Chlorhexidine impregnated dressings
Change if signs of infection (erythema/purulence/fever)
Use dedicated line for RRT only
Remove as soon as RRT no longer needed

Troubleshooting

Low blood flow: Check catheter position (CXR/USS); patient positioning; line kinking; try reversing ports
High pressure alarms: Clotting in line — flush with NaCl; check circuit
Circuit clotting: review anticoagulation, pre-filter citrate level (CRRT)
Recirculation: femoral catheters prone to recirculation if too short

AKI in the GCC Context

GCC-Specific Burden: The Gulf region faces a distinct AKI epidemiology driven by high T2DM prevalence, hypertension, extreme heat, sickle cell disease, high contrast use, and traditional medicine practices. GCC nurses must understand these regional factors.

Diabetes & Hypertension Nephropathy

GCC has world's highest T2DM prevalence (20–25% adults in some countries)
Diabetic nephropathy = leading cause of CKD in GCC, creating vulnerable patients with reduced AKI threshold
Hypertension prevalence 30–40% in GCC adults
Combination of DM + HTN dramatically increases AKI susceptibility
These patients often on ACEi/ARB + NSAID simultaneously — high AKI risk combination
Regular eGFR monitoring essential in all diabetic/hypertensive patients

Contrast-Induced AKI — High Incidence

GCC hospitals perform very high volumes of cardiac catheterisation/angiography due to high cardiovascular disease burden
Many patients have combined risk factors: DM + CKD + contrast
Pre-hydration protocols mandatory in all GCC cardiac catheterisation labs
All interventional cardiology units should have nephrology liaison
Creatinine and eGFR must be checked before all elective contrast procedures
Radiology and cardiology departments need standardised CI-AKI prevention pathways

Rhabdomyolysis from Heat Stroke — Occupational Risk

Construction workers — majority from South Asia (India, Pakistan, Bangladesh, Nepal) working outdoors in summer temperatures of 45–50°C
Heat stroke = core temperature >40°C + CNS dysfunction → massive rhabdomyolysis → AKI
Exertional heat stroke: high CK, myoglobinuria, AKI, DIC, hepatic dysfunction
Saudi Arabia, Qatar, UAE: high incidence during June–September

Rapid cooling is the treatment priority (cold water immersion or evaporative cooling)
Aggressive IV fluid 200–300 mL/hr, targeting UO >200 mL/hr
Monitor CK, creatinine, electrolytes, coagulation
Admission to ICU in severe cases
Policy advocacy: limit outdoor work during peak heat hours (10am–4pm during summer)
GCC countries have introduced labour protections — midday work bans in summer

Sickle Cell Disease & AKI

High sickle cell prevalence: Eastern Saudi Arabia, Bahrain, Oman (HbSS, HbSC, HbS-β thalassaemia)
Sickle cell nephropathy: tubular dysfunction early, then glomerular disease, progressing to CKD
Papillary necrosis: medullary ischaemia → sloughing of papillae → haematuria, ureteric obstruction, AKI — presents as acute flank pain + haematuria
Proteinuria: from focal segmental glomerulosclerosis — ACEi for proteinuria reduction (hold in AKI)
Vaso-occlusive crisis → rhabdomyolysis → AKI
Increased susceptibility to contrast nephropathy — pre-hydrate aggressively
Avoid dehydration, hypoxia, cold, acidosis (all precipitate sickling)

MERS-CoV Associated AKI

Middle East Respiratory Syndrome Coronavirus — endemic in Arabian Peninsula (camel reservoir)
AKI occurs in up to 50% of severe MERS hospitalised cases
Mechanism: direct tubular cell invasion by MERS-CoV, shock-mediated ATN, drug nephrotoxicity (antivirals), cytokine-mediated injury
AKI a major predictor of mortality in MERS
RRT frequently required in ICU MERS cases
Avoid nephrotoxic medications in MERS patients
Strict isolation nursing: PPE compliance essential (respiratory transmission)

Herbal Medicine Nephrotoxicity — GCC

Widespread use of traditional herbal medicines across all GCC countries
Arabic traditional medicine: "Tibb Al-Nabawi" preparations
Asian traditional medicines common in large expatriate South/Southeast Asian population
Aristolochic acid present in some preparations — irreversible tubulointerstitial nephritis
Language and cultural barriers may prevent disclosure to medical staff
Non-judgemental history-taking essential: "Do you take any herbal, traditional, or natural remedies?"
Document all traditional remedies in medication history
Pharmacy teams should screen for potential nephrotoxic components

🏥Nephrology Service Development in GCC

Current Status

Rapid growth of nephrology services across GCC over past two decades
Saudi Arabia: Saudi Society of Nephrology; comprehensive tertiary nephrology centres
Qatar: HMC Hamad Medical Corporation nephrology — advanced CRRT and transplant services
UAE: Sheikh Khalifa Medical City, Cleveland Clinic Abu Dhabi — tertiary renal services
Bahrain, Kuwait, Oman: growing nephrology infrastructure
Dialysis capacity expanded significantly to meet CKD/ESRD burden

Nursing Workforce Considerations

High proportion of expatriate nursing workforce — important to understand GCC-specific AKI triggers
Cultural competence: communication with patients in Arabic (use certified interpreters)
Religious considerations: Ramadan fasting — AKI risk from dehydration; medication timing adjustment
Patient education: Arabic-language resources about AKI prevention (avoid NSAIDs, stay hydrated, regular diabetes monitoring)
Documentation in both English and Arabic systems common in GCC hospitals

📋AKI Prevention — Arabic Patient Education Points

Key Messages for Patients

تثقيف المرضى / Patient Education (Arabic Summary)
The following points should be communicated to patients (use certified interpreters):

Avoid NSAIDs (ibuprofen / بروفين) especially if diabetic or hypertensive
Stay well hydrated especially in hot weather — minimum 2–3L water/day in summer
Inform doctors of ALL medicines including herbal/traditional
Attend regular diabetes and blood pressure monitoring appointments
Report reduced urine output, leg swelling, or unusual fatigue promptly

High-Risk Groups for AKI Prevention Education

Diabetic patients: annual eGFR, urine ACR, avoid nephrotoxins, maintain hydration
Hypertensive patients: regular BP monitoring, avoid NSAID use (use paracetamol instead)
Cardiac patients pre-angiography: pre-procedure hydration counselling
Outdoor workers: hydration education, recognize heat stroke symptoms
Sickle cell patients: hydration, temperature regulation, prompt medical attention for pain crises
Ramadan fasting: medication adjustment planning with medical team before Ramadan

AKI Staging Calculator & Management Guide

Enter patient data to calculate KDIGO AKI stage and receive stage-specific management guidance.

Baseline Creatinine (μmol/L)

Current Creatinine (μmol/L)

Patient Weight (kg)

Urine Output Over Last 6 Hours (mL)

Serum Potassium — K+ (mmol/L) (optional)

pH / Blood Gas pH (optional)

Hours Since Onset (for UO criteria) (optional)

Stage-Specific Management Actions

Nephrotoxin Review Checklist

Check each nephrotoxin — tick when reviewed and stopped/assessed.

NSAIDs (ibuprofen, diclofenac, naproxen, ketorolac, indomethacin) — STOP immediately

ACE Inhibitors (ramipril, enalapril, lisinopril, perindopril) — HOLD until AKI resolved

ARBs (losartan, valsartan, irbesartan, candesartan) — HOLD until AKI resolved

Metformin — HOLD (lactic acidosis risk). Restart when creatinine stable & eGFR >30

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) — STOP

Aminoglycosides (gentamicin, amikacin, tobramycin) — Assess necessity; if continuing: levels monitoring, single daily dosing

Vancomycin — AUC-guided dosing; avoid with piperacillin-tazobactam unless necessary; monitor levels

IV Contrast — Defer if possible; if essential: pre-hydration protocol, minimum volume, low-osmolar contrast

Diuretics (thiazides/loop) — Review: stop if hypovolaemia; furosemide only for fluid overload management in AKI

Ciclosporin / Tacrolimus — Check levels; nephrology input for dose adjustment

Amphotericin B — Use liposomal form; monitor K+, Mg²+, creatinine daily

Herbal / traditional medicines — Ask patient; document all; stop until safety established

Tenofovir (HIV) — Monitor urine protein/phosphate; nephrology input; switch to tenofovir alafenamide (TAF) if possible

Dose adjustment reviewed — All renally-cleared medications reviewed and doses adjusted for current eGFR (check renal drug handbook)

RRT Criteria Checker — AEIOU Assessment

Mark criteria present to assess whether RRT is indicated.

A — Acidosis: Metabolic acidosis pH <7.15 refractory to medical management (bicarbonate therapy, treatment of underlying cause)

E — Electrolytes: Hyperkalaemia K+ >6.5 mmol/L refractory to medical treatment (calcium gluconate + insulin-dextrose + salbutamol + resonium) — or immediate life-threatening hyperkalaemia with ECG changes

I — Intoxication: Dialysable toxin ingestion — methanol, ethylene glycol, lithium, salicylates, metformin (severe lactic acidosis with organ failure), valproate (severe)

O — Overload: Fluid overload refractory to diuretics (pulmonary oedema, inability to maintain adequate nutrition, haemodynamic compromise from fluid burden)

U — Uraemia: Symptomatic uraemia — encephalopathy, uraemic pericarditis, uraemic coagulopathy/bleeding. (Serum urea alone not an indication; symptoms required unless rapidly rising)

Advanced AKI Nursing — GCC